In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington’s disease focussed project, which supported Alchemab in securing significant private investment.
Alchemab pioneers a data-driven approach to antibody therapeutics by identifying highly resilient subjects and learning how their antibodies overcome or resist disease. It uses them to develop therapeutic products for broader use in patients who lack the protective response.
This funding enabled Alchemab to exploit its target-agnostic drug discovery platform further, focusing on developing novel therapeutics for hard-to-treat neurodegenerative diseases and cancers.
The Alchemab and MDC collaboration was extended in 2022 to functionally characterise antibodies from resilient patients with Alzheimer’s disease and frontotemporal dementia. Alchemab’s approach, developing new therapeutics founded on natural resilience to disease rather than the disease itself, combined with MDC’s technologies and expertise, significantly improves understanding of the pathophysiology and treatment opportunities for Huntington’s disease and Alzheimer’s disease. This approach has great potential to be applied to many other areas of currently unmet patient needs.